GlaxoSmithKline's cancer vaccine MAGE-A3 suffers its second PhIII flop

GlaxoSmithKline's once high-flying hopes in the cancer vaccine MAGE-A3 have crashed to earth--for a second time. Once a top Phase III program at the pharma giant, MAGE-A3 failed to hit a pair of primary endpoints for non-small cell lung cancer, its second ... Read Full Story